Denali Therapeutics (DNLI) Competitors $16.64 +0.58 (+3.58%) As of 12:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DNLI vs. ROIV, LNTH, RVMD, BBIO, LEGN, TGTX, TLX, BPMC, SRPT, and AXSMShould you be buying Denali Therapeutics stock or one of its competitors? The main competitors of Denali Therapeutics include Roivant Sciences (ROIV), Lantheus (LNTH), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), TG Therapeutics (TGTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Blueprint Medicines (BPMC), Sarepta Therapeutics (SRPT), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. Denali Therapeutics vs. Roivant Sciences Lantheus Revolution Medicines BridgeBio Pharma Legend Biotech TG Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Blueprint Medicines Sarepta Therapeutics Axsome Therapeutics Denali Therapeutics (NASDAQ:DNLI) and Roivant Sciences (NASDAQ:ROIV) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, community ranking, earnings and media sentiment. Which has higher earnings and valuation, DNLI or ROIV? Roivant Sciences has lower revenue, but higher earnings than Denali Therapeutics. Roivant Sciences is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDenali Therapeutics$330.53M7.06-$145.22M-$2.57-6.25Roivant Sciences$122.59M67.41$4.35B-$0.15-77.20 Does the MarketBeat Community prefer DNLI or ROIV? Denali Therapeutics received 412 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 78.57% of users gave Roivant Sciences an outperform vote while only 68.58% of users gave Denali Therapeutics an outperform vote. CompanyUnderperformOutperformDenali TherapeuticsOutperform Votes46768.58% Underperform Votes21431.42% Roivant SciencesOutperform Votes5578.57% Underperform Votes1521.43% Do analysts recommend DNLI or ROIV? Denali Therapeutics presently has a consensus price target of $37.57, indicating a potential upside of 133.94%. Roivant Sciences has a consensus price target of $17.50, indicating a potential upside of 51.12%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Denali Therapeutics is more favorable than Roivant Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Denali Therapeutics 0 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 2 Strong Buy rating(s) 3.06Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more risk and volatility, DNLI or ROIV? Denali Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Do institutionals & insiders have more ownership in DNLI or ROIV? 92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 7.9% of Denali Therapeutics shares are owned by insiders. Comparatively, 7.9% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is DNLI or ROIV more profitable? Denali Therapeutics has a net margin of 0.00% compared to Roivant Sciences' net margin of -119.54%. Roivant Sciences' return on equity of -14.05% beat Denali Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Denali TherapeuticsN/A -32.94% -30.04% Roivant Sciences -119.54%-14.05%-12.81% Does the media refer more to DNLI or ROIV? In the previous week, Roivant Sciences had 3 more articles in the media than Denali Therapeutics. MarketBeat recorded 13 mentions for Roivant Sciences and 10 mentions for Denali Therapeutics. Roivant Sciences' average media sentiment score of 1.63 beat Denali Therapeutics' score of 1.45 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 12 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryDenali Therapeutics beats Roivant Sciences on 10 of the 18 factors compared between the two stocks. Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNLI vs. The Competition Export to ExcelMetricDenali TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.33B$2.95B$5.53B$7.93BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-5.8230.0722.5118.54Price / Sales7.06494.82397.62103.30Price / CashN/A168.6838.1834.62Price / Book2.163.176.734.25Net Income-$145.22M-$72.35M$3.22B$248.18M7 Day Performance2.42%2.14%1.38%1.03%1 Month Performance16.89%5.67%2.79%2.70%1 Year Performance-4.46%-23.57%15.41%4.05% Denali Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNLIDenali Therapeutics4.156 of 5 stars$16.64+3.6%$37.57+125.9%-0.6%$2.42B$330.53M-6.03430Upcoming EarningsPositive NewsGap UpROIVRoivant Sciences2.1957 of 5 stars$10.04-1.1%$17.50+74.3%+3.3%$7.16B$122.59M-66.93860Positive NewsLNTHLantheus3.9716 of 5 stars$100.62-0.7%$129.43+28.6%+57.2%$6.89B$1.53B16.74700Upcoming EarningsPositive NewsRVMDRevolution Medicines3.7491 of 5 stars$36.56-0.5%$66.67+82.3%+4.7%$6.80B$742,000.00-10.18250Upcoming EarningsPositive NewsBBIOBridgeBio Pharma4.5588 of 5 stars$33.51-1.1%$53.00+58.2%+42.1%$6.37B$221.90M-11.76400Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageLEGNLegend Biotech2.6714 of 5 stars$32.24-1.7%$79.00+145.0%-22.8%$5.92B$627.24M-33.941,070TGTXTG Therapeutics3.3132 of 5 stars$36.97-3.5%$40.67+10.0%+185.7%$5.81B$329.00M-369.66290Upcoming EarningsPositive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.21-3.0%$22.00+35.7%N/A$5.48B$783.21M0.00N/AAnalyst RevisionNews CoverageGap DownBPMCBlueprint Medicines1.7409 of 5 stars$84.18-0.6%$124.95+48.4%+4.6%$5.38B$508.82M-77.94640Earnings ReportAnalyst ForecastNews CoveragePositive NewsSRPTSarepta Therapeutics4.7589 of 5 stars$55.23+2.7%$158.70+187.3%-52.0%$5.36B$1.90B44.18840Upcoming EarningsAXSMAxsome Therapeutics4.8309 of 5 stars$103.00-1.4%$169.80+64.9%+49.9%$5.02B$385.69M-17.20380Upcoming EarningsAnalyst ForecastShort Interest ↓News CoveragePositive News Related Companies and Tools Related Companies Roivant Sciences Competitors Lantheus Competitors Revolution Medicines Competitors BridgeBio Pharma Competitors Legend Biotech Competitors TG Therapeutics Competitors Telix Pharmaceuticals Limited American Depositary Shares Competitors Blueprint Medicines Competitors Sarepta Therapeutics Competitors Axsome Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DNLI) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMassive red flag about American consumerWhy is the U.S. Dollar suddenly crashing? Pundits on either side of the aisle have been warning that the U....Stansberry Research | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DNLI Stock Free DNLI Stock Alerts